Nicola Klein to United States
This is a "connection" page, showing publications Nicola Klein has written about United States.
Connection Strength
2.408
-
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
Score: 0.128
-
Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States. Ann Intern Med. 2022 12; 175(12):1169-1771.
Score: 0.113
-
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022 04 01; 5(4):e228879.
Score: 0.109
-
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
Score: 0.108
-
Shouting at each other into the void: A linguistic network analysis of vaccine hesitance and support in online discourse regarding California law SB277. Soc Sci Med. 2020 12; 266:113216.
Score: 0.097
-
Use of acellular pertussis vaccines in the United States: can we do better? Expert Rev Vaccines. 2017 12; 16(12):1175-1179.
Score: 0.080
-
Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Vaccine. 2017 06 16; 35(28):3564-3574.
Score: 0.078
-
Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
Score: 0.073
-
Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. Pediatr Infect Dis J. 2016 06; 35(6):662-72.
Score: 0.073
-
Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015 Feb; 135(2):e321-9.
Score: 0.066
-
Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother. 2014; 10(9):2684-90.
Score: 0.065
-
Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013 Jun; 131(6):e1716-22.
Score: 0.059
-
Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012 May; 129(5):809-14.
Score: 0.054
-
Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J. 2012 Jan; 31(1):64-71.
Score: 0.053
-
Underimmunization at discharge from the neonatal intensive care unit. J Perinatol. 2012 May; 32(5):363-7.
Score: 0.052
-
Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years. Expert Rev Vaccines. 2008 Nov; 7(9):1309-20.
Score: 0.043
-
Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J. 2008 Apr; 27(4):341-6.
Score: 0.041
-
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
Score: 0.032
-
Lack of Evidence for Vaccine-Associated Enhanced Disease From COVID-19 Vaccines Among Adults in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2024 08; 33(8):e5863.
Score: 0.032
-
Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstet Gynecol. 2024 Aug 01; 144(2):215-222.
Score: 0.032
-
COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV. JAMA Netw Open. 2024 Jun 03; 7(6):e2415220.
Score: 0.032
-
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
Score: 0.031
-
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
Score: 0.030
-
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
Score: 0.028
-
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
Score: 0.027
-
A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine. 2022 02 23; 40(9):1246-1252.
Score: 0.027
-
Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
Score: 0.027
-
The Childhood Vaccination Schedule and the Lack of Association With Type 1 Diabetes. Pediatrics. 2021 12 01; 148(6).
Score: 0.027
-
A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016. Vaccine. 2021 12 20; 39(52):7598-7605.
Score: 0.026
-
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
Score: 0.026
-
COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 29; 70(43):1520-1524.
Score: 0.026
-
Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021 10 01; 40(10):944-951.
Score: 0.026
-
Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
Score: 0.026
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 13; 70(32):1094-1099.
Score: 0.026
-
COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
Score: 0.026
-
Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
Score: 0.025
-
Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial. Vaccine. 2021 03 05; 39(10):1534-1543.
Score: 0.025
-
SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
Score: 0.024
-
Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. J Immunol. 2020 08 15; 205(4):877-882.
Score: 0.024
-
Association Between Rotavirus Vaccination and Type 1 Diabetes in Children. JAMA Pediatr. 2020 05 01; 174(5):455-462.
Score: 0.024
-
Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016-17 season. Vaccine. 2020 02 24; 38(9):2202-2208.
Score: 0.023
-
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
Score: 0.023
-
Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
Score: 0.022
-
Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine. 2019 05 31; 37(25):3296-3302.
Score: 0.022
-
Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics. 2018 03; 141(3).
Score: 0.020
-
Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
Score: 0.020
-
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017 12 14; 35(49 Pt B):6879-6884.
Score: 0.020
-
Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
Score: 0.020
-
Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
Score: 0.019
-
Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
Score: 0.019
-
Risk of Preterm or Small-for-Gestational-Age Birth After Influenza Vaccination During Pregnancy: Caveats When Conducting Retrospective Observational Studies. Am J Epidemiol. 2016 08 01; 184(3):176-86.
Score: 0.018
-
Influenza Vaccination During Pregnancy: Influenza Seasons 2002-2012, Vaccine Safety Datalink. Am J Prev Med. 2016 Apr; 50(4):480-488.
Score: 0.017
-
Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015 Jan 03; 33(2):382-7.
Score: 0.016
-
Does preventing rotavirus infections through vaccination also protect against naturally occurring intussusception over time? Clin Infect Dis. 2015 Jan 01; 60(1):163-4.
Score: 0.016
-
The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014 Sep 22; 32(42):5390-8.
Score: 0.016
-
Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
Score: 0.016
-
Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014 Jun; 133(6):e1492-9.
Score: 0.016
-
Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine. Vaccine. 2014 May 23; 32(25):3019-24.
Score: 0.016
-
Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014 Feb 06; 370(6):513-9.
Score: 0.015
-
Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis. 2014 Jan; 58(2):173-7.
Score: 0.015
-
Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. Pediatr Infect Dis J. 2013 Feb; 32(2):163-8.
Score: 0.014
-
Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. Am J Epidemiol. 2013 Jan 15; 177(2):131-41.
Score: 0.014
-
Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: a randomized, controlled, open-label, multicenter study. Vaccine. 2012 May 14; 30(23):3360-8.
Score: 0.014
-
Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA. 2012 Feb 08; 307(6):598-604.
Score: 0.013
-
Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011 Aug; 165(8):749-55.
Score: 0.013
-
Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. Pediatrics. 2011 May; 127 Suppl 1:S65-73.
Score: 0.013
-
The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011 May; 127 Suppl 1:S45-53.
Score: 0.013
-
Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine. 2010 Jan 08; 28(3):657-63.
Score: 0.011
-
Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
Score: 0.011